HRP20120084A2 - FULVESTRANT U DOZI OD 500 mg ZA LIJEČENJE UZNAPREDOVALOG RAKA DOJKE - Google Patents

FULVESTRANT U DOZI OD 500 mg ZA LIJEČENJE UZNAPREDOVALOG RAKA DOJKE Download PDF

Info

Publication number
HRP20120084A2
HRP20120084A2 HR20120084A HRP20120084A HRP20120084A2 HR P20120084 A2 HRP20120084 A2 HR P20120084A2 HR 20120084 A HR20120084 A HR 20120084A HR P20120084 A HRP20120084 A HR P20120084A HR P20120084 A2 HRP20120084 A2 HR P20120084A2
Authority
HR
Croatia
Prior art keywords
fulvestrant
patients
treatment
breast cancer
dose
Prior art date
Application number
HR20120084A
Other languages
English (en)
Croatian (hr)
Inventor
William Dimery Isaiah
Webster Alan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120084(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20120084A2 publication Critical patent/HRP20120084A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HR20120084A 2009-07-27 2010-07-26 FULVESTRANT U DOZI OD 500 mg ZA LIJEČENJE UZNAPREDOVALOG RAKA DOJKE HRP20120084A2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0912999.0A GB0912999D0 (en) 2009-07-27 2009-07-27 Method-803
PCT/GB2010/051228 WO2011012885A1 (en) 2009-07-27 2010-07-26 Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer

Publications (1)

Publication Number Publication Date
HRP20120084A2 true HRP20120084A2 (hr) 2012-04-30

Family

ID=41066853

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120084A HRP20120084A2 (hr) 2009-07-27 2010-07-26 FULVESTRANT U DOZI OD 500 mg ZA LIJEČENJE UZNAPREDOVALOG RAKA DOJKE

Country Status (36)

Country Link
US (1) US20120214778A1 (enExample)
EP (1) EP2459199A1 (enExample)
JP (1) JP2013500324A (enExample)
KR (1) KR20120042843A (enExample)
AT (1) AT510868A2 (enExample)
AU (1) AU2010277373A1 (enExample)
BG (1) BG111123A (enExample)
BR (1) BR112012001837A2 (enExample)
CA (1) CA2768286A1 (enExample)
CL (1) CL2012000226A1 (enExample)
CZ (1) CZ201235A3 (enExample)
DE (1) DE112010003084T5 (enExample)
DK (1) DK201270089A (enExample)
EA (1) EA201200190A1 (enExample)
EC (1) ECSP12011629A (enExample)
EE (1) EE201200003A (enExample)
ES (1) ES2393323A1 (enExample)
FI (1) FI20125207L (enExample)
GB (2) GB0912999D0 (enExample)
HR (1) HRP20120084A2 (enExample)
HU (1) HUP1200203A3 (enExample)
IL (1) IL217527A0 (enExample)
IS (1) IS8994A (enExample)
LT (1) LT5953B (enExample)
MX (1) MX2012001282A (enExample)
NO (1) NO20120147A1 (enExample)
PE (1) PE20121177A1 (enExample)
PL (1) PL399129A1 (enExample)
RO (1) RO128705A2 (enExample)
RS (1) RS20120022A1 (enExample)
SE (1) SE1250155A1 (enExample)
SG (1) SG177586A1 (enExample)
SK (1) SK500052012A3 (enExample)
TR (1) TR201200950T1 (enExample)
WO (1) WO2011012885A1 (enExample)
ZA (1) ZA201201406B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
RU2016148441A (ru) * 2014-05-21 2018-06-22 Ф. Хоффманн-Ля Рош Аг Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом
WO2017201189A1 (en) * 2016-05-17 2017-11-23 Abraxis Bioscience, Llc Methods for assessing neoadjuvant therapies
MX386903B (es) * 2016-10-21 2025-03-19 Crescita Therapeutics Inc Composiciones farmacéuticas tópicas y uso en el tratamiento de afecciones cutáneas.
US20180153868A1 (en) * 2016-12-06 2018-06-07 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
KR102267378B1 (ko) * 2019-09-10 2021-06-21 가천대학교 산학협력단 C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
GB201201486D0 (en) 2012-03-14
PE20121177A1 (es) 2012-09-23
FI20125207A7 (fi) 2012-02-23
LT5953B (lt) 2013-07-25
US20120214778A1 (en) 2012-08-23
RO128705A2 (ro) 2013-08-30
KR20120042843A (ko) 2012-05-03
MX2012001282A (es) 2012-06-12
CL2012000226A1 (es) 2012-08-31
EP2459199A1 (en) 2012-06-06
GB0912999D0 (en) 2009-09-02
LT2012006A (lt) 2013-03-25
ECSP12011629A (es) 2012-02-29
SK500052012A3 (sk) 2012-04-03
IS8994A (is) 2012-02-24
ES2393323A1 (es) 2012-12-20
GB2484050A (en) 2012-03-28
NO20120147A1 (no) 2012-04-03
BR112012001837A2 (pt) 2016-03-15
WO2011012885A9 (en) 2011-03-24
DE112010003084T5 (de) 2012-09-06
PL399129A1 (pl) 2012-11-19
HUP1200203A1 (en) 2012-09-28
EA201200190A1 (ru) 2012-08-30
AT510868A2 (de) 2012-07-15
BG111123A (bg) 2012-10-31
SG177586A1 (en) 2012-02-28
EE201200003A (et) 2012-04-16
RS20120022A1 (sr) 2012-10-31
DK201270089A (en) 2012-02-24
CA2768286A1 (en) 2011-02-03
FI20125207L (fi) 2012-02-23
HUP1200203A3 (en) 2012-12-28
WO2011012885A1 (en) 2011-02-03
JP2013500324A (ja) 2013-01-07
AU2010277373A1 (en) 2012-02-09
SE1250155A1 (sv) 2012-02-22
TR201200950T1 (tr) 2012-09-21
ZA201201406B (en) 2013-08-28
CZ201235A3 (cs) 2012-06-27
IL217527A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
Modugno et al. Hormone response in ovarian cancer: time to reconsider as a clinical target?
Croxtall et al. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women
US20110183949A1 (en) Use of Fulvestrant in the Treatment of Resistant Breast Cancer
Gadducci et al. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer
NO20120147A1 (no) Fulvestrant i en dose pa 500 mg for behandling av fremskreden brystkreft
AU2001244372A1 (en) Use of fulvestrant in the treatment of resistant breast cancer
AU2012100098A4 (en) Fulvestrant in a dosage of 500mg for the treatment of advanced breast cancer
Catania et al. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre
Goldhirsch et al. Adjuvant chemotherapy in premenopausal patients: a more complicated form of oophorectomy?
CN101404988A (zh) 乳腺癌治疗方案
KR20260006644A (ko) 유방암 치료에 사용하기 위한 카피바서티브, cdk4/6 억제제 및 풀베스트란트의 조합
Komaranchath Adjuvant Endocrine Therapy in Early Breast Cancer
Morrow et al. 10 Breast-Cancer Prevention
HK1051498B (en) Use of fulvestrant in the treatment of resistant breast cancer
HK1081842A (en) Use of fulvestrant in the treatment of resistant breast cancer

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130604

Year of fee payment: 4

OBST Application withdrawn